CUE
No price yet
Announcements
Nothing here yet
Daily updates
- Cue Biopharma reported positive Phase 2 results for CUE-221 in 145 patients with chronic spontaneous urticaria, meeting the primary and key secondary endpoints with strong statistical significance and a favorable tolerability profile.Oct 21, 2026
- Cue Biopharma reported positive Phase 2 CUE-221 data in chronic spontaneous urticaria, meeting all primary endpoints and the key secondary endpoint at 4 mg/kg with significant placebo-adjusted improvements and a favorable safety profile.Sep 21, 2026
FDA designations
Nothing here yet
News
- Cue Biopharma reported positive topline results from the Phase 2 CUE-221 study in chronic spontaneous urticariaSep 21, 2026
- Cue Biopharma reported preclinical safety and tolerability data for CUE-401 in autoimmune and inflammatory diseasesFeb 17, 2026
- Cue Biopharma and ImmunoScape announce strategic collaboration to develop breakthrough cell therapy approach for solid tumorsNov 6, 2025
- Cue Biopharma announces initiation of investigator-sponsored trial of CUE-102 in recurrent glioblastoma multiformeAug 13, 2025
- Cue Biopharma reports new complete response and confirms 50% overall response rate in ongoing Phase 1 trial of CUE-101 plus pembrolizumab for recurrent/metastatic HPV+ head and neck cancerJul 16, 2025